Takamochi et al. reported coexisting EGFR and K-ras mutations in two (2%) of 82 patients with lung adenocarcinomas [36], and our result showed that there were 14 (28.6%) patients with both EGFR and K-ras mutations in the primary lung adenocarcinomas. Here, KRAS is linked to lung adenocarcinoma.